Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis

被引：0
|
作者：
Hadji, P. [1 ]
Asmar, L. [2 ]
Van Nes, J. G. [3 ]
Menschik, T. [4 ]
Hasenburg, A. [5 ]
Kuck, J. [6 ]
Nortier, H. [3 ]
Jones, S. [2 ]
Van der Velde, C. [3 ]
Ziller, M. [1 ]
机构：
[1] Univ Marburg, Marburg, Germany
[2] US Oncol Res Inc, Houston, TX USA
[3] Leiden Univ, Med Ctr, Leiden, Netherlands
[4] Pfizer Oncol, Paris, France
[5] Univ Freiburg, Freiburg, Germany
[6] Independent Clin Res Consulting, Berlin, Germany
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [21] Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: Results of a prospective randomized study
    Kieback, D. G.
    Harbeck, N.
    Bauer, W.
    Hadji, P.
    Weyer, G.
    Hasenburg, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
    van de Velde, Cornelis J. H.
    Rea, Daniel
    Seynaeve, Caroline
    Putter, Hein
    Hasenburg, Annette
    Vannetzel, Jean-Michel
    Paridaens, Robert
    Markopoulos, Christos
    Hozumi, Yasuo
    Hille, Elysee T. M.
    Kieback, Dirk G.
    Asmar, Lina
    Smeets, Jan
    Nortier, Johan W. R.
    Hadji, Peyman
    Bartlett, John M. S.
    Jones, Stephen E.
    LANCET, 2011, 377 (9762): : 321 - 331
  • [23] Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
    van Hezewijk, Marjan
    Bastiaannet, Esther
    Putter, Hein
    Scholten, Astrid N.
    Liefers, Gerrit-Jan
    Rea, Daniel
    Hasenburg, Annette
    Paridaens, Robert
    Hozumi, Yasuo
    Markopoulos, Christos
    Seynaeve, Caroline
    Jones, Stephen E.
    Marijnen, Corrie A. M.
    van de Velde, Cornelis J. H.
    RADIOTHERAPY AND ONCOLOGY, 2013, 108 (02) : 190 - 196
  • [24] CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
    Dezentje, Vincent O.
    Gelderblom, Hans
    Van Schaik, Ron H. N.
    Vletter-Bogaartz, Judith M.
    Van der Straaten, Tahar
    Wessels, Judith A. M.
    Kranenbarg, Elma Meershoek-Klein
    Berns, Els M.
    Seynaeve, Caroline
    Putter, Hein
    Van de Velde, Cornelis J. H.
    Nortier, Johan W. R.
    Guchelaar, Henk-Jan
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) : 171 - 179
  • [25] CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
    Vincent O. Dezentjé
    Hans Gelderblom
    Ron H. N. Van Schaik
    Judith M. Vletter-Bogaartz
    Tahar Van der Straaten
    Judith A. M. Wessels
    Elma Meershoek-Klein Kranenbarg
    Els M. Berns
    Caroline Seynaeve
    Hein Putter
    Cornelis J. H. Van de Velde
    Johan W. R. Nortier
    Henk-Jan Guchelaar
    Breast Cancer Research and Treatment, 2014, 143 : 171 - 179
  • [26] Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
    Fontein, Duveken B. Y.
    Seynaeve, Caroline
    Hadji, Peyman
    Hille, Elysee T. M.
    de Water, Willemien van
    Putter, Hein
    Kranenbarg, Elma Meershoek-Klein
    Hasenburg, Annette
    Paridaens, Robert J.
    Vannetzel, Jean-Michel
    Markopoulos, Christos
    Hozumi, Yasuo
    Bartlett, John M. S.
    Jones, Stephen E.
    Rea, Daniel William
    Nortier, Johan W. R.
    van de Velde, Cornelis J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) : 2257 - U59
  • [27] Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
    van, Nes J. G. H.
    Papapoulos, S. E.
    Braun, J. J.
    Dirix, L.
    Putter, H.
    Zwaan, R. E.
    Ballieux, B. E. P.
    van Rongen, I
    van de Velde, C. J. H.
    Seynaeve, C.
    Nortier, J. W. R.
    CANCER RESEARCH, 2009, 69 (02) : 152S - 153S
  • [28] Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer
    van de Velde, C.
    Seynaeve, C.
    Hasenburg, A.
    Rea, D.
    Vannetzel, J. M.
    Paridaens, R.
    Markopoulos, C.
    Smeets, J.
    Nortier, J. W. R.
    Jones, S. E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 1 - 1
  • [29] Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy
    Jones, Stephen E.
    Cantrell, James
    Vukelja, Svetislava
    Pippen, John
    O'Shaughnessy, Joyce
    Blum, Joanne L.
    Brooks, Robert
    Hartung, Nicole L.
    Negron, Angel G.
    Richards, Donald A.
    Rivera, Ragene
    Holmes, Frankie Ann
    Chittoor, Sreeni
    Whittaker, Thomas L.
    Bordelon, James H.
    Ketchel, Steven J.
    Davis, Jennifer C.
    Ilegbodu, Des
    Kochis, Jean
    Asmar, Lina
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4765 - 4771
  • [30] Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
    van Nes, J. G. H.
    Seynaeve, C.
    Maartense, E.
    Roumen, R. M. H.
    de Jong, R. S.
    Beex, L. V. A. M.
    Kranenbarg, W. M. Meershoek-Klein
    Putter, H.
    Nortier, J. W. R.
    van de Velde, C. J. H.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 974 - 982
12345